Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement.
D001757:Blastomeres / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000276:immunology / Q000648:ultrastructure; D003167:Complement Activation; D003176:Complement C3 / Q000302:isolation & purification / Q000494:pharmacology; D003180:Complement C3b Inactivator Proteins / Q000302:isolation & purification / Q000494:pharmacology; D003182:Complement C5 / Q000302:isolation & purification / Q000494:pharmacology; D003183:Complement C6 / Q000302:isolation & purification / Q000494:pharmacology; D003184:Complement C7 / Q000302:isolation & purification / Q000494:pharmacology; D003185:Complement C8 / Q000302:isolation & purification / Q000494:pharmacology; D003186:Complement C9 / Q000302:isolation & purification / Q000494:pharmacology; D011415:Complement Factor B / Q000302:isolation & purification / Q000494:pharmacology; D011416:Complement Factor D / Q000302:isolation & purification / Q000494:pharmacology; D003170:Complement Pathway, Alternative; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects*; D008242:Lysogeny / Q000187:drug effects*; D011414:Properdin / Q000302:isolation & purification / Q000494:pharmacology
D003176:Complement C3; D003180:Complement C3b Inactivator Proteins; D003182:Complement C5; D003183:Complement C6; D003184:Complement C7; D003185:Complement C8; D003186:Complement C9; D011414:Properdin; C493488:CFD protein, human; D011416:Complement Factor D; D011415:Complement Factor B